EU/3/20/2361: Orphan designation for the treatment of congenital pulmonary hypoplasia

Perflubron

Table of contents

Overview

On 13 November 2020, orphan designation EU/3/20/2361 was granted by the European Commission to Boyd Consultants Limited, Ireland, for perflubron for the treatment of congenital pulmonary hypoplasia.

The sponsor’s address was updated in September 2021.

Key facts

Active substance
Perflubron
Intented use
Treatment of congenital pulmonary hypoplasia
Orphan designation status
Positive
EU designation number
EU/3/20/2361
Date of designation
13/11/2020
Sponsor

Boyd Consultants Limited
6th Floor
South Bank House
Barrow Street
Dublin
Dublin 4
Ireland
E-mail: regulatory@boydconsultants.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating